678161-30-3

Upstream product

• 13121-99-8 pyridin-4-ylacetonitrile 
• 459-57-4 4-fluorobenzaldehyde 
• 678161-28-9 methyl 3-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-pyrrole-2-carboxylate 
• 678161-29-0 methyl 3-(4-fluorophenyl)-1-methyl-4-(pyridin-4-yl)-1H-pyrrole-2-carboxylate 

Downstream Products

• 678161-34-7 4-[4-(4-fluoro-phenyl)-5-methoxycarbonyl-1-methyl-3-pyridin-4-yl-1H-pyrrol-2-yl]-piperazine-1-carboxylic acid tert-butyl ester 
• 678161-35-8 3-(4-fluorophenyl)-1-methyl-5-(1-piperazinyl)-4-(4-pyridinyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 678161-38-1 3-(4-fluorophenyl)-1-methyl-5-(4-methyl-1-piperazinyl)-4-(4-pyridinyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 678163-17-2 5-bromo-3-(4-fluorophenyl)-1-methyl-4-pyridin-4-yl-1H-pyrrole-2-carbonitrile 

Relevant academic research and scientific papers

Inhibitors of unactivated p38 MAP kinase

Inhibition of the p38 map kinase pathway has been shown to be beneficial in the treatment of inflammatory diseases. The first class of potent p38 kinase inhibitors was the pyridinylimidazole compounds from SKB. Since then several pyridinylimidazole-based

3,4-DISUBSTITUTED PYRROLES AND THEIR FOR USE IN TREATING INFLAMMATORY DISEASES

This invention provides novel substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by reducing TNF-α production and/or p38 activity in appropriate cells. This